Anti-anxiety and antidepressant medications have helped many who struggle with depression and anxiety over the years. However, the treatments aren’t effective in some individuals, which prompts them to look for alternative treatment options. New research has found that more individuals suffering from depression and/or anxiety are using marijuana products to manage their symptoms.
Results from prior studies on depression and marijuana are mixed, with a 2019 study reporting that teenage cannabis use was linked to depression. However, some synthetic or isolated components of marijuana have demonstrated a short-term decrease in anxiety.
This new study was led by Erin Martin, a neuroscientist from the Medical University of South Carolina. It recruited more than 500 participants, 170 of whom did not use marijuana.
The team administered an online survey that asked various questions regarding the participants’ use of marijuana, chronic pain issues, quality of life, sleep, depression and anxiety. The researchers utilized the Hospital Anxiety and Depression Scale (“HADS”) to examine each of the participants’ experiences. On this scale, a score can be as high as 20, but any score above 8 signals clinical concern.
The researchers found that the individuals who were consuming marijuana products had lower levels of depression, noting that a bigger proportion of those who consumed marijuana also scored less than eight on the HADS scale in comparison to the control group. Marijuana users also reported that their quality of life was higher and that their sleep was better in the last month in comparison to the control group.
In addition, in follow-up studies, the researchers found that the anxiety of a fraction of the those who hadn’t used decreased when they consumed marijuana. Furthermore, the researchers discovered that the effect of the plant was potent among individuals who used products with higher amounts of CBD in comparison with THC products.
In their report, the researchers note that, at baseline, no effect of medicinal marijuana use on anxiety was observed. They added that marijuana’s potency wasn’t impacted by individuals who consumed conventional antidepressants.
The study had various limitations, including the fact that this was a self-reported questionnaire, which makes it more difficult to find out the exact effects of the drug. The researchers note that more research is needed to find out whether individuals who can’t or don’t want to take anti-anxiety and antidepressant medications could do so without repercussions.
It should be noted that the study’s data isn’t a recommendation to quit the use of prescribed medications and use marijuana as a depression or anxiety buster. The study was reported in “Frontiers in Psychiatry.”
This research makes a strong case for giving cannabis and CBD medicinal in particular, including those manufactured by entities such as Simply Sonoma Inc., a closer look to ascertain their potential medical benefits.
NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma Inc. are available in the company’s newsroom at https://cnw.fm/Sonoma
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.